医学部附属病院

猪狩 英俊

イガリ ヒデトシ  (Hidetoshi Igari)

基本情報

所属
千葉大学 医学部附属病院 感染制御部 教授 (感染制御部長)
学位
医学博士

J-GLOBAL ID
200901048909387877
researchmap会員ID
1000284759

研究キーワード

 2

学歴

 2

論文

 120
  • Yuriko Yamazaki, Tomoka Ito, Seitaro Nakagawa, Takashi Sugihira, Chinami Kurita-Tachibana, Amer E. Villaruz, Kensuke Ishiguro, Barbora Salcman, Shuo Li, Sanami Takada, Naohiro Inohara, Yoko Kusuya, Aki Shibata, Masakazu Tamai, Reika Aoyama, Kanako Inoue, Shota Murata, Kazuyuki Matsushita, Akiko Miyabe, Toshibumi Taniguchi, Hidetoshi Igari, Naruhiko Ishiwada, Masateru Taniguchi, Taka-Aki Nakada, Hiroyuki Matsue, Manabu Fujimoto, Haruka Hishiki, Yoshiteru Osone, Hiromichi Hamada, Naoki Shimojo, Tsutomu Suzuki, Michael Otto, Gabriel Núñez, Hiroki Takahashi, Akiko Takaya, Yuumi Nakamura
    Nature Communications 15(1) 2024年11月7日  
  • Hidetoshi Igari, Seiichiro Sakao, Takayuki Ishige, Kengo Saito, Shota Murata, Misuzu Yahaba, Toshibumi Taniguchi, Akiko Suganami, Kazuyuki Matsushita, Yutaka Tamura, Takuji Suzuki, Eiji Ido
    Nature Communications 15(1) 2024年4月29日  
    Abstract Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of viral RNA polymerase, has become a valuable therapeutic agent. However, immunosuppressed hosts may respond inadequately to RDV and develop chronic persistent infections. A patient with respiratory failure caused by interstitial pneumonia, who had undergone transplantation of the left lung, developed COVID-19 caused by Omicron BA.5 strain with persistent chronic viral shedding, showing viral fusogenicity. Genome-wide sequencing analyses revealed the occurrence of several viral mutations after RDV treatment, followed by dynamic changes in the viral populations. The C799F mutation in nsp12 was found to play a pivotal role in conferring RDV resistance, preventing RDV-triphosphate from entering the active site of RNA-dependent RNA polymerase. The occurrence of diverse mutations is a characteristic of SARS-CoV-2, which mutates frequently. Herein, we describe the clinical case of an immunosuppressed host in whom inadequate treatment resulted in highly diverse SARS-CoV-2 mutations that threatened the patient’s health due to the development of drug-resistant variants.
  • Ami Aoki, Chiaki Iwamura, Masahiro Kiuchi, Kaori Tsuji, Atsushi Sasaki, Takahisa Hishiya, Rui Hirasawa, Kota Kokubo, Sachiko Kuriyama, Atsushi Onodera, Tadanaga Shimada, Tetsutaro Nagaoka, Satoru Ishikawa, Akira Kojima, Haruki Mito, Ryota Hase, Yasunori Kasahara, Naohide Kuriyama, Sukeyuki Nakamura, Takashi Urushibara, Satoru Kaneda, Seiichiro Sakao, Osamu Nishida, Kazuhisa Takahashi, Motoko Y. Kimura, Shinichiro Motohashi, Hidetoshi Igari, Yuzuru Ikehara, Hiroshi Nakajima, Takuji Suzuki, Hideki Hanaoka, Taka-aki Nakada, Toshiaki Kikuchi, Toshinori Nakayama, Koutaro Yokote, Kiyoshi Hirahara
    Journal of Clinical Immunology 44(4) 2024年4月22日  
    Abstract Purpose Auto-antibodies (auto-abs) to type I interferons (IFNs) have been identified in patients with life-threatening coronavirus disease 2019 (COVID-19), suggesting that the presence of auto-abs may be a risk factor for disease severity. We therefore investigated the mechanism underlying COVID-19 exacerbation induced by auto-abs to type I IFNs. Methods We evaluated plasma from 123 patients with COVID-19 to measure auto-abs to type I IFNs. We performed single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells from the patients with auto-abs and conducted epitope mapping of the auto-abs. Results Three of 19 severe and 4 of 42 critical COVID-19 patients had neutralizing auto-abs to type I IFNs. Patients with auto-abs to type I IFNs showed no characteristic clinical features. scRNA-seq from 38 patients with COVID-19 revealed that IFN signaling in conventional dendritic cells and canonical monocytes was attenuated, and SARS-CoV-2-specific BCR repertoires were decreased in patients with auto-abs. Furthermore, auto-abs to IFN-α2 from COVID-19 patients with auto-abs recognized characteristic epitopes of IFN-α2, which binds to the receptor. Conclusion Auto-abs to type I IFN found in COVID-19 patients inhibited IFN signaling in dendritic cells and monocytes by blocking the binding of type I IFN to its receptor. The failure to properly induce production of an antibody to SARS-CoV-2 may be a causative factor of COVID-19 severity.
  • 戸来 依子, 横田 翔, 吉川 寛, 矢幅 美鈴, 谷口 俊文, 村田 正太, 千葉 均, 猪狩 英俊
    日本呼吸器学会誌 13(増刊) 278-278 2024年3月  
  • Yui Sakai, Toshibumi Taniguchi, Yoriko Herai, Misuzu Yahaba, Akira Watanabe, Katsuhiko Kamei, Hidetoshi Igari
    Cureus 16(2) e53550 2024年2月  
    We report the case of an 84-year-old man with a history of IgG4-related sclerosing cholangitis who was diagnosed with advanced esophageal cancer and underwent radiation and chemotherapy. An implantable central venous access port was placed for chemotherapy and total parenteral nutrition. The patient presented with a fever and received antimicrobial therapy for acute cholangitis but remained febrile, and subsequently, yeast was detected in the aerobic bottle of blood culture obtained from the central venous line. The yeast was identified as Wickerhamomyces anomalus. Liposomal amphotericin B was administered, and the central line access port was removed. After confirmation of negative blood cultures and 14 days post treatment, he underwent reinsertion of the central line access port. Due to persistent pain at the insertion site, fluconazole was added for an additional 14 days, and the patient was discharged and transferred to another hospital. Wickerhamomyces anomalus is a rare fungal infection with other synonyms including Pichia anomala, Hansenula anomala, and Candida pelliculosa. A literature review of 53 case reports of Wickerhamomyces anomalus, Pichia anomala, Hansenula anomala, and Candida pelliculosa was conducted, with a total of 211 cases reviewed. Fungemia was reported in 94% of cases, with central venous catheterization, parental feeding, low birth weight, and immunocompromised status identified as major risk factors. The majority of cases were pediatric, particularly neonatal, and there were reports of nosocomial infections causing outbreaks, with some cases involving the eye such as endophthalmitis or keratitis.

MISC

 134
  • 猪狩英俊
    臨床と微生物 51 2024年1月  筆頭著者
  • 田代萌, 谷口俊文, 伊藤菜穂子, 渡邉未来, 猪狩英俊
    日本エイズ学会誌 25(2) 76-83 2023年5月31日  
  • 猪狩 英俊
    感染と消毒 30(1) 62-65 2023年5月  
    ISSN 1346-2326 ISSN-L 1346-2326
  • Shuhei Nagai, Hidemi Niwa, Yuki Terajima, Hiroki Igari, Young-Chang P. Arai, Toshihiko Yamashita, Toshihiko Taguchi, Masaya Nakamura, Takahiro Ushida
    Journal of Clinical Medicine 12(4) 1324-1324 2023年2月7日  
    Background: Numbness is a term commonly used in clinical practice to describe an abnormal sensory experience that is produced by a stimulus or is present even without a stimulus. However, there is still much that remains obscure in this field, and also, few reports have focused on its symptoms. In addition, while pain itself is known to have a significant impact on quality of life (QOL), the relationship between numbness and QOL is often unclear. Therefore, we conducted an epidemiological survey and analyzed the relationship between painless numbness and QOL, using type, location, and age as influencing factors, respectively. Methods: A nationwide epidemiological survey was conducted by mail using a survey panel designed by the Nippon Research Center. Questionnaires were sent to 10,000 randomly selected people aged 18 and over from all over Japan. Out of the 5682 people who responded, the relationship between numbness and QOL was analyzed using the EuroQol 5 Dimension-3L (EQ5D-3L) for patients who are currently experiencing painless numbness. Findings: The results suggest that painless numbness affects QOL and that QOL decreases as its intensity increases. Furthermore, the two factors of numbness of feet and numbness among the young may be less likely to affect QOL. This study may be of great significance in the field of numbness research.
  • 今泉優理, 石毛崇之, 藤川樹, 庭野亜美, 宮部安規子, 村田正太, 川崎健治, 西村基, 谷口俊文, 猪狩英俊, 松下一之
    日本遺伝子診療学会大会プログラム・抄録集 30th 2023年  

書籍等出版物

 18

講演・口頭発表等

 52

共同研究・競争的資金等の研究課題

 11

社会貢献活動

 41

メディア報道

 15